Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa Maria, California.
| Revenue (TTM) | $129.47M |
| Gross Profit (TTM) | $40.61M |
| EBITDA | $8.24M |
| Operating Margin | 7.51% |
| Return on Equity | -76.40% |
| Return on Assets | -3.04% |
| Revenue/Share (TTM) | $3.46 |
| Book Value | $-0.90 |
| Price-to-Book | 197.99 |
| Price-to-Sales (TTM) | 1.87 |
| EV/Revenue | 2.365 |
| EV/EBITDA | 8.11 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -3.80% |
| Shares Outstanding | $37.91M |
| Float | $19.34M |
| % Insiders | 3.04% |
| % Institutions | 72.49% |
Volatility is currently contracting
CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at three upcoming industry events.
BALA CYNWYD, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lifecore Biomedical, Inc. (NasdaqGS: LFCR) to Webster Equity Partners. Under the terms of the proposed transaction, shareholders of Lifecore will receive $6.28 in cash for each share of Lifecore that they own. KSF is seeking to determine whether this consideration and the process that led to it.
BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - September 29, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lifecore Biomedical, Inc. ("Lifecore Biomedical" or the "Company") (NASDAQ: LFCR) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Webster Equity Partners for $6.28 per share in cash at closing plus one non-tradable contingent value right (CVR) per share. The investigation concerns whether the Lifecore Biomedical Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the proposed transaction is paying fair value to shareholders of the Company.
Lifecore shareholders will receive just $6.28 per share in a transaction valued at up to $663.7 million; Ademi LLP is investigating the deal price, benefits to company insiders, and restrictions on competing offers CLICK HERE TO JOIN MILWAUKEE, Sept. 28, 2026 /PRNewswire/ -- Ademi LLP is investigating whether the proposed acquisition of Lifecore (Nasdaq: LFCR) by Webster Equity Partners, provides fair value to Lifecore's public shareholders and whether Lifecore's Board adequately protected shareholder interests in negotiating and approving the transaction.
Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Premium Lifecore Series A Preferred Stockholders Will Receive Required “Conversion Amount” per Share in Cash at Closing Both Common Stockholders and Series A Preferred Stockholders Will Receive Contingent Value Rights (CVRs) for Up to $160 Million in Aggregate Cash Payments Contingent Upon Achieving Performance Milestones Stockholders May Receive Up to $9.67 per Common Equivalent in Combined Cash and CVR at Full Performance Milestone Payments Transaction Expected to Support Lifecore's Growth Objectives CHASKA, Minn. and WALTHAM, Mass.
CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the CPHI Global Conference.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LFCR and any ticker you trade — then tracks every position and per-strategy win rate.
